Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study.
In Sweden, the former is included in national guidelines despite poor scientific support and the latter is not used clinically. This study investigates the prognostic properties of these variables, together with classical histopathological variables, in multivariate analysis in a stringently stratified material.
Material and method:
A consecutive, population-based patient material restricted to FIGO 2009 stage I endometroid endometrial carcinoma (n=1140) was retrospectively collected from routinely reported data from medical records. Data on age, FIGO stage, degree of differentiation, S-phase fraction, DNA ploidy status, and adjuvant treatment were included in the study.
Cumulative incidence curves with other causes of death as a competing risk were used for univariable analysis for the primary endpoint endometrial cancer death. Cox proportional hazards regression analysis was used for multivariate modeling of all endpoints, and for univariable analysis for the secondary endpoints overall survival and time to progression.
Results: An S-phase fraction value of > 5.5% was associated with worse outcome (for endometrial cancer death: hazard ratio = 2.25; 95% CI 1.38-3.67; p = 0.001, adjusted) and DNA ploidy status was not, for all endpoints tested.
Conclusions:
In FIGO stage I endometroid endometrial carcinoma, DNA ploidy status had no prognostic value, while S-phase fraction may be used to identify those with a higher risk of adverse clinical outcome . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 Definition of the optimal cut-off for S-phase fraction is overdue now that the prognostic power has been established. , which has not been found by others (8) (9) (10) (11) . Likewise, SPF has been found to have (8, (12) (13) (14) and not found to have prognostic value in different studies (15) , and some authors have reported independent prognostic value of both variables in multivariable analysis (16) (17) (18) .
As previously reported, our laboratory has improved the DNA flow cytometric protocol considerably, leading to more reliable and reproducible measurements of both DNA ploidy and SPF (19).
In this study, we wanted to investigate the prognostic value of DNA ploidy and SPF in International Federation of Gynecology and Obstetrics (FIGO) stage I EC of endometroid histology in a large unselected population-based patient material.
Material and methods

Patients
Data from all reported cases of uterine cancer in the Southern Swedish Healthcare Region 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Up to 20,000 events were collected for each sample. A DNA aneuploid control sample (with known DNA index and SPF) was run in parallel in order to control for the conditions of the FCM instrument, the preparation of cell nuclei, and the stability and quality of DNA staining.
Samples with one G0/G1 peak and a corresponding G2 peak were considered diploid, and those with two or more G0/G1 peaks were considered aneuploid. Tetraploid tumours, defined as having a DNA index of 1.9-2.1, were included in the aneuploid group. In cases of aneuploidy, SPF was reported for the aneuploid population. Since there is no established cut-off value for SPF, the mean SPF value was used in the construction of a high and a low SPF group.
Follow-up
Vital status was checked using the Total Population Register and the Swedish Cause of Death Register. End of follow-up was December 2012 for cause-of-death data, August 2012 for followup on progression from medical journals, and January 2014 for death from any cause.
Statistical analysis
The primary endpoint of the study was death from endometrial cancer (i.e. where death with underlying or contributing cause C54 or C55 in International Statistical Classification of Diseases and Related Health Problems -Tenth Revision was considered an event). Secondary endpoints were (1) overall survival (OS) and (2) time to progression (TTP), i.e. time from diagnosis to first local, regional, or distant recurrence.
For death from endometrial cancer, cumulative incidence curves, separated according to SPF and DNA ploidy status, were calculated treating death from other causes as a competing event. SPF was dichotomized using the mean as the cut-point before any prognostic analyses were run. To obtain p-values, hazard ratios, and for multivariable modelling, Cox proportional hazard regression was used. For Cox regression for endometrial cancer death, death from other causes was considered to be a censoring event, i.e. cause-specific Cox regression was performed.
Similarly, in the analysis of TTP, death from any cause was considered a censoring event. Adjusted hazard ratios were obtained by including age (with levels < 65, 65-75, and > 75), FIGO stage (IA or IB), degree of differentiation ("well-differentiated" or "poorly differentiated"), SPF ("low" or "high"), DNA ploidy status (diploid or aneuploid), and adjuvant treatment ("yes" or "no") in the Cox model. Most p-values were calculated using Wald tests, except for "age"-for which a likelihood-ratio test was used.
Fisher's exact test was used to compare the distribution of categorical variables between aneuploid and diploid tumours and between tumours of high and low SPF. Student's t-test was used to check for significance of differences in means of continuous variables. Statistical analysis was done using Stata 13.1/SE (StataCorp, College Station, TX, USA).
Power calculation
When planning the study, a power calculation was performed using group and effect sizes from a pilot study of the effects of SPF and DNA ploidy status on 5-year OS. For SPF, we anticipated groups of equal sizes, and that the 5-year OS would be 90% in women with tumours with low SPF. Thus, for a hazard ratio (HR) of 2, five hundred patients would be needed in order to achieve 80% power to detect the effect. For DNA ploidy status, we anticipated that 80% of the women would have diploid tumours, and that the 5-year OS in these women would be 80%. For an HR of 2, three hundred patients would be needed to achieve 80% power. Using seven consecutive years, we expected 1,160 patients in the Southern Swedish Healthcare Region, thus giving comfortable margins for detection of effects, even after accounting for fewer deaths from endometrial cancer than from all causes, and for using multivariable analyses.
Results
Patient characteristics
Median age at diagnosis was 68 years (mean 68, range 32-92). There were 1,137 patients graded for differentiation, 1,030 in the "well-differentiated" group (91%) and 107 in the "poorly differentiated" group (9%). 890 patients (78%) had been graded according to FIGO criteria, and 247 (21.7%) by subjective degree of differentiation. Only 3 patients (0.3%) had no histological grading. There were 865 patients in stage IA (76%) and 275 (24%) in stage IB. Only 68 patients (6%) had received adjuvant treatment (Table 2 and Fig. 1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w DNA ploidy status could be evaluated for 1,069 of the patients (94%), 889 (83%) of whom had diploid tumours and 180 (17%) of whom had aneuploid tumours. For SPF, 234 patients (21%) had no evaluation, generally because of low resolution of the histograms through background debris. For the remaining patients, the mean SPF was 5.5%-giving 553 patients (61%) below the threshold and 353 patients (39%) above the threshold. All cases that could be evaluated regarding SPF could also be evaluated regarding DNA ploidy status (Table 2 and Fig. 1 ). The mean coefficient of variation of the diploid G0/G1 peak in all DNA histograms was 3.5%.
Flow cytometry
Death from endometrial cancer
Median follow-up time for death from EC was 8.9 years for patients who were still alive at the end of follow-up. In total, 105 patients died of endometrial cancer during the follow-up period, 85 of them within the first 5 years after diagnosis. Figure 2 shows the cumulative incidence curves of death from endometrial cancer, according to SPF and DNA ploidy status. In univariable analysis, a high SPF value was associated with worse outcome (HR = 2.95; 95% CI 1.9-4.7; p < 0.001) than a low SPF value, and similarly for aneuploid vs. 
Overall survival
Median follow-up time for OS was 9.2 years for patients who were alive at the end of follow-up.
Altogether, 315 patients died, 170 of whom had died within 5 years. A high SPF value was associated with worse outcome, both in univariable analysis (HR = 1.65; 95% CI 1.28-2.13; p < 0.001) and in multivariable analysis (HR = 1.50; 95% CI 1.15-1.95; p = 0.003), whereas DNA ploidy status did not retain its prognostic value after adjustment for measured confounders. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 4 ). An extended list of univariable and multivariable results regarding OS and TTP can be found in Supporting Information Table S1 .
Time to progression
Median follow-up time for TTP was 7.8 years for patients who were alive without recurrence at the end of follow-up. Altogether, 125 patients (11%) had a recurrence during the follow-up period, 114 of whom had a recurrence within 5 years. There were 73 vaginal recurrences (59%), 12 pelvic recurrences (10%), 39 distant recurrences (31%), and 1 (1%) with missing location. A high SPF value was highly associated with worse outcome when adjusted for included factors (HR = 2.24; 95% CI 1.5-3.4; p < 0.001, full follow-up period). This applied to both time frames.
DNA ploidy status was not associated with worse outcome (Table 4) .
Discussion
Our results show that SPF has independent prognostic value, whereas DNA ploidy does not, when included in multivariable analysis of endometrial cancer death, OS and TTP.
Some of the patients with aneuploid tumours, with other concomitant risk factors, had undergone adjuvant vaginal brachytherapy (VBT) and/or external pelvic beam radiotherapy (EBRT) as part of routine care. This could possibly explain some of the loss of prognostic information for DNA ploidy status. To assess the direct effect of ploidy on prognosis, not mediated by treatment effect, we adjusted for treatment in our main analysis. In a stability analysis, we investigated the influence of SPF and DNA ploidy status in untreated patients only. Selection of untreated patients may introduce bias due to the other risk factors (FIGO stage and degree of differentiation) that, together with DNA ploidy status, affect the use of adjuvant therapy. By adjusting for these risk factors, however, the problem is reduced. Altogether, only 52 of 905 patients included in the multivariable analysis (6%) received adjuvant treatment, 34 of whom had aneuploid tumours and 18 of whom had diploid. The increased hazard of aneuploidy was very similar, adjusted for the other risk factors, irrespective of whether treated patients were included or excluded. In all, the loss of prognostic information for DNA ploidy status could not be explained by increased use of adjuvant therapy in the aneuploid group.
In this study, death from EC was defined as death with EC as the underlying or contributory 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 low-risk cases, no effect was seen in the VBT-treated arm (27). Thus, it appears that aneuploidy does not add an increased risk of recurrence and that VBT does not alter the recurrence rate significantly on histopathologically low-risk cases.
Variations in prognostic value for SPF and DNA ploidy can often be traced back to differences in inclusion criteria, with different studies using various mixes of stages and histological types.
The studies that have found DNA ploidy to be significant as a prognostic factor have often Gudmundsson et al. found that DNA ploidy and SPF have different prognostic value depending on the histological grade. In their low-risk group, SPF was found to be a very strong independent predictor of survival whereas DNA ploidy had no prognostic value. This contrasted with their high-risk group in which DNA ploidy was an independent prognostic factor while SPF lost significance in the multivariate analysis (13) . By copying their study design, which included all 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w FIGO stages, we too found DNA ploidy to be significant in the high-risk group but not in the low-risk group (data not shown).
The discrepancies between the results in our study and those cited above can thus be explained by differences in inclusion criteria and methodology, which might explain some of the controversy in this field. It highlights the importance of taking such differences into account when comparing studies.
In accordance with our study, Wagenius et al. showed independent prognostic value for SPF, but not for DNA ploidy, in a prospective study stratified for FIGO stage I-II; they also showed that there was a correlation between higher SPF and earlier recurrence (29).
Image cytometry has been shown to be superior to FCM in identifying aneuploid cases (30), but it cannot give a reliable estimation of SPF due to the low cell numbers in the histograms. FCM is also superior to Ki-67 immunohistochemistry for quantification of cell proliferation in EC (14) .
In our material, 234 cases (21%) could not be evaluated regarding SPF. However, since the DNA FCM protocol in the national guidelines was updated in 2008, there have been dramatic improvements in DNA histogram quality, i.e. less contribution from debris and a shift in the coefficient of variation from 4.5-5.5% to 2.0-2.5% for the diploid G0/G1 peak. Thus, nowadays SPF is reported in ~95% of the EC samples analyzed (unpublished data).
It would be valuable for future studies to look into optimizing the cut-off value for SPF when FCM is used on hysterectomy and curettage samples. Studies concentrating on survival analysis and recurrence patterns should carefully stratify patients according to international FIGO criteria for stage and grade, in order to avoid erroneous conclusions based on arbitrary group constructions.
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